Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance

Traders Union
All News
Companies
Madrigal Pharmaceuticals down 1.56% today

Highlights

MDGL maintains a strong bullish trend, trading well above key moving averages with support at $494 and potential resistance near $560.
Despite bullish momentum, overbought signals from several short-term indicators suggest risk of a near-term pullback or consolidation.
Weekly outlook projects price action within a $464 to $560 range, with an 80% probability of further upside as long-term signals remain positive.

MDGL is trading at $510.68, well above its MA-20 ($447.75), MA-50 ($464.66), and MA-200 ($442.24). This alignment signals continuing bullish momentum across short-, medium-, and long-term trends. The Ichimoku Kijun at $494.21 sits below the current price, acting as immediate support. Near-term support is located at the Ichimoku Kijun ($494.21), with key support at MA-50 ($464.66). Near-term resistance is set at MA-100 ($508.44), followed by key resistance at the recent price zone around MA-200 ($442.24), though this level now functions more as historical support given the rally.

Momentum signals remain positive, with D1 MACD neutral but ADX indicating a buy and AO in alignment with the broader uptrend. However, several oscillators—RSI (68.04), CCI (278.68), Stoch RSI (88.78), and BBP (59.14)—are in or near overbought territory, suggesting a risk of short-term pullback as buyers dominate intraday action. In today's session, MDGL has slipped 1.56%, reflecting some cooling after last week's substantial rally. Since the start of the week, MDGL has climbed from $441.16 to $510.68, a notable 15.76% gain, positioning it in the middle of this week's range. Weekly volatility stands at 30.92%, with the tone consolidating near the midpoint after a sharp advance and subsequent retracement from the highs.

Looking ahead, the expected price range for the coming week is $464.00 to $560.00. This forecast is anchored against the 52-week low ($265.00) and high ($615.00), with the current price near the upper half of the yearly range. Weekly signals are bullish, with all key indicators on W1—MA-50, RSI, ADX, and MACD—giving buy signals, resulting in a very high probability (more than 80%) of upward price movement and a very low probability of a decline. The baseline scenario is for MDGL to consolidate in a wide band as overbought conditions resolve. In the bullish case, a break above $560.00 could set up a move toward retesting yearly highs. The bearish scenario would require a sustained drop below $494.00, opening the door to a correction toward the $464.00 region.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Madrigal Pharmaceuticals participated in the 6th Annual Liver Connect Conference, highlighting increased engagement within the liver health community. With market attention now focused elsewhere, traders should monitor for shifts in sentiment that could impact Madrigal Pharmaceuticals’ near-term price action.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.